pp-159 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
Switzerland
GMP approvals
EU GMP
Comments
Indication: Moderate-to-severe hidradenitis suppurativa (HS); psoriatic arthritis (PsA)
Clinical stage: Phase 3
Modality: Biologic (trivalent nanobody: anti-IL-17A/F Nanobody + anti-Albumin Nanobody for half-life extension)
Mechanism / Target: Simultaneously neutralises IL-17A and IL-17F — dual inhibition provides broader blockade than IL-17A-only agents (secukinumab, ixekizumab); albumin binding extends half-life
Route / form: Subcutaneous injection (monthly maintenance)
Differentiation: IL-17A+F dual inhibition may be superior in HS/PsA vs IL-17A-only; nanobody technology enables multivalent design; monthly SC dosing
Manufacturer #39186
Clinical-stage immunology company specialising in nanobody-based therapies for chronic inflammatory diseases. Develops trivalent IL-17A/F nanobodies with differentiated dual-cytokine inhibition profile. Wholly owned Phase 3 pipeline in hidradenitis suppurativa and psoriatic arthritis.
None